

# Preclinical development of a MET degrader as a novel NSCLC agent

InnoCure Therapeutics, Inc



ONCOLOGY	Preclinical
Product Type	Synthetic Drugs, TPD (Targeted-Protein Degradation)
Indication	1 <sup>st</sup> indication : NSCLC with MET amplification/overexpression/Exon14 skipping 2 <sup>nd</sup> indication : Gastric Cancer, Colon cancer and advanced solid cancers
Target	Mesenchymal-epithelial transition factor receptor (MET)
MoA(Mechanism of Action)	Degradation of amplified, overexpressed and skipped mutation of MET
Competitiveness	<ol style="list-style-type: none"> <li>1. Global leader in MET degrader for NSCLC</li> <li>2. Very selective inhibition of MET in 468 Kinase assays (Kinome scan).</li> <li>3. Degradation with InnoCure's proprietary ELCBIL (E3 ligase binder library) to strengthen IP and MILPROTAC to enhance oral availability</li> <li>4. Degradation showing superior in vitro and in vivo efficacies to those of inhibitors</li> <li>5. Promising the use of combination therapy (degrader + EGFR TKI's)</li> </ol>
Development Stage	Preclinical
Route of Administration	PO(QD)